1
|
Boruta T, Ścigaczewska A, Bizukojć M. "Microbial Wars" in a Stirred Tank Bioreactor: Investigating the Co-Cultures of Streptomyces rimosus and Aspergillus terreus, Filamentous Microorganisms Equipped With a Rich Arsenal of Secondary Metabolites. Front Bioeng Biotechnol 2021; 9:713639. [PMID: 34660550 PMCID: PMC8511322 DOI: 10.3389/fbioe.2021.713639] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Accepted: 09/17/2021] [Indexed: 11/13/2022] Open
Abstract
Microbial co-cultivation is an approach frequently used for the induction of secondary metabolic pathways and the discovery of novel molecules. The studies of this kind are typically focused on the chemical and ecological aspects of inter-species interactions rather than on the bioprocess characterization. In the present work, the co-cultivation of two textbook producers of secondary metabolites, namely Aspergillus terreus (a filamentous fungus used for the manufacturing of lovastatin, a cholesterol-lowering drug) and Streptomyces rimosus (an actinobacterial producer of an antibiotic oxytetracycline) in a 5.5-L stirred tank bioreactor was investigated in the context of metabolic production, utilization of carbon substrates and dissolved oxygen levels. The cultivation runs differed in terms of the applied co-culture initiation strategy and the composition of growth medium. All the experiments were performed in three bioreactors running in parallel (corresponding to a co-culture and two respective monoculture controls). The analysis based upon mass spectrometry and liquid chromatography revealed a broad spectrum of more than 40 secondary metabolites, including the molecules identified as the oxidized derivatives of rimocidin and milbemycin that were observed solely under the conditions of co-cultivation. S. rimosus showed a tendency to dominate over A. terreus, except for the runs where S. rimosus was inoculated into the already developed bioreactor cultures of A. terreus. Despite being dominated, the less aggressive strain still had an observable influence on the production of secondary metabolites and the utilization of substrates in co-culture. The monitoring of dissolved oxygen levels was evaluated as a fast approach of identifying the dominant microorganism during the co-cultivation process.
Collapse
Affiliation(s)
- Tomasz Boruta
- Department of Bioprocess Engineering, Faculty of Process and Environmental Engineering, Lodz University of Technology, Lodz, Poland
| | - Anna Ścigaczewska
- Department of Bioprocess Engineering, Faculty of Process and Environmental Engineering, Lodz University of Technology, Lodz, Poland
| | - Marcin Bizukojć
- Department of Bioprocess Engineering, Faculty of Process and Environmental Engineering, Lodz University of Technology, Lodz, Poland
| |
Collapse
|
2
|
Kolahdouz M, Jafari F, Falanji F, Nazemi S, Mohammadzadeh M, Molavi M, Amin B. Clavulanic Acid Attenuating Effect on the Diabetic Neuropathic Pain in Rats. Neurochem Res 2021; 46:1759-1770. [PMID: 33846883 DOI: 10.1007/s11064-021-03308-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Revised: 10/24/2020] [Accepted: 03/18/2021] [Indexed: 12/27/2022]
Abstract
Diabetic neuropathy is one of the most common complications of diabetes mellitus. Excess glutamate release and oxidative stress are hypothesized to be involved in the pathophysiology of diabetes-induced neuropathy. This study was designed to investigate the effect of clavulanic acid (CLAV), a competitive beta-lactamase inhibitor, on the streptozocin (STZ)-induced neuropathic pain and possible mechanisms in the spinal cord of rats. Male Wistar rats were divided into naive group; control group which got a single dose of STZ (50 mg/kg, i.p.), as a model of diabetic neuropathic pain; prophylactic groups: animals received CLAV (10, 20 and 40 mg/kg, i.p.) 1 week after STZ for 10 days; and therapeutic group: animals received 20 mg/kg CLAV, 21 days after STZ for 10 days. Study of pain behaviors was started on days 0, 7, 14, 21, 28, 35 and 42 after STZ. The expression of the glutamate transport 1 (GLT1), genes of oxidative stress including inducible nitric oxide synthase (iNOS), proinflammatory cytokine, tumor necrosis factor alpha (TNF-α), as well as genes involved in the apoptosis including bcl2, bcl2-associated x (bax) were measured in the spinal cord tissue by Real Time PCR, on day 42. On day 21 post injection of STZ, diabetic animals showed significant mechanical allodynia, cold allodynia and thermal hyperalgesia. CLAV in all doses of 10, 20 and 40 mg/kg reduced symptoms of allodynia and hyperalgesia, in both prophylactic and therapeutic regimens. While iNOS, TNF-α, bax/bcl2 were found significantly overexpressed in spinal cord of diabetic animals, their expression in animals received CLAV had been reduced. In contrast, GLT1 that had decreased in the spinal cord of diabetic animals, significantly increased in those received CLAV. CLAV was found a promising candidate for reliving neuropathic pain in diabetes mellitus. Such beneficial effect of CLAV could be, in part, attributed to the increased expression of GLT 1, inhibition of nitrosative stress, anti-inflammation, and inhibition of some apoptotic mediators followed by administration into diabetic animals.
Collapse
Affiliation(s)
- Mahnoush Kolahdouz
- Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Faranak Jafari
- Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Farahnaz Falanji
- Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Samad Nazemi
- Cellular and Molecular Research Center, Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Mohammad Mohammadzadeh
- Cellular and Molecular Research Center, Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Mehdi Molavi
- Department of Internal Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
| | - Bahareh Amin
- Cellular and Molecular Research Center, Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.
| |
Collapse
|
3
|
Althobaiti YS, Alshehri FS, Hakami AY, Hammad AM, Sari Y. Effects of Clavulanic Acid Treatment on Reinstatement to Methamphetamine, Glial Glutamate Transporters, and mGluR 2/3 Expression in P Rats Exposed to Ethanol. J Mol Neurosci 2018; 67:1-15. [PMID: 30471010 DOI: 10.1007/s12031-018-1194-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Accepted: 10/01/2018] [Indexed: 11/24/2022]
Abstract
Evidence demonstrated that the glutamatergic system is implicated in mediating relapse to several drugs of abuse, including methamphetamine (METH). Glutamate homeostasis is maintained by a number of glutamate transporters, such as glutamate transporter type 1 (GLT-1), cystine/glutamate transporter (xCT), and glutamate aspartate transporter (GLAST). In addition, group II metabotropic glutamate receptors (mGluR2/3) were found to be implicated in relapse-seeking behavior. Ample evidence showed that β-lactam antibiotics are effective in upregulating GLT-1 and xCT expression, thus improving glutamate homeostasis and attenuating relapse to drugs of abuse. In this study, we investigated the reinstatement of METH using conditioned place preference (CPP) in male alcohol-preferring (P) rats exposed to home-cage free choice ethanol drinking. Here, we tested the effect of clavulanic acid (CA), a β-lactam, on the reinstatement of METH-seeking and ethanol drinking. In addition, we examined the expression of GLT-1, xCT, and GLAST as well as metabotropic glutamate receptor (mGluR2/3) in the nucleus accumbens (NAc) shell, NAc core, and dorsomedial prefrontal cortex (dmPFC). A priming i.p. injection of METH reinstated preference in METH-paired chamber following extinction. Chronic exposure to ethanol decreased the expression of GLT-1 and xCT in the NAc shell, but not in the NAc core or dmPFC. CA treatment blocked the reinstatement of METH-seeking, decreased ethanol intake, and restored the expression of GLT-1 and xCT in the NAc shell. In addition, the expression of mGluR2/3 was increased by CA treatment in the NAc shell and dmPFC. These findings suggest that these glutamate transporters and mGluR2/3 might be potential therapeutic targets for the attenuation of reinstatement to METH-seeking.
Collapse
Affiliation(s)
- Yusuf S Althobaiti
- College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Experimental Therapeutics, University of Toledo, Health Science Campus, 3000 Arlington Avenue, HEB 282G, Toledo, OH, 43614, USA.,College of Pharmacy, Department of Pharmacology and Toxicology, Taif University, Taif, Saudi Arabia
| | - Fahad S Alshehri
- College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Experimental Therapeutics, University of Toledo, Health Science Campus, 3000 Arlington Avenue, HEB 282G, Toledo, OH, 43614, USA
| | - Alqassem Y Hakami
- College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Experimental Therapeutics, University of Toledo, Health Science Campus, 3000 Arlington Avenue, HEB 282G, Toledo, OH, 43614, USA
| | - Alaa M Hammad
- College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Experimental Therapeutics, University of Toledo, Health Science Campus, 3000 Arlington Avenue, HEB 282G, Toledo, OH, 43614, USA
| | - Youssef Sari
- College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacology and Experimental Therapeutics, University of Toledo, Health Science Campus, 3000 Arlington Avenue, HEB 282G, Toledo, OH, 43614, USA.
| |
Collapse
|
4
|
Kim J, John J, Langford D, Walker E, Ward S, Rawls SM. Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice. Amino Acids 2015; 48:689-696. [PMID: 26543027 DOI: 10.1007/s00726-015-2117-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Accepted: 10/09/2015] [Indexed: 01/11/2023]
Abstract
The β-lactam antibiotic ceftriaxone (CTX) reduces cocaine reinforcement and relapse in preclinical assays through a mechanism involving activation of glutamate transporter subtype 1 (GLT-1). However, its poor brain penetrability and intravenous administration route may limit its therapeutic utility for indications related to CNS diseases. An alternative is clavulanic acid (CA), a structural analog of CTX that retains the β-lactam core required for GLT-1 activity but displays enhanced brain penetrability and oral activity relative to CTX. Here, we tested the hypothesis that CA (1, 10 mg/kg ip) would enhance GLT-1 expression and decrease cocaine self-administration (SA) in mice, but at lower doses than CTX. Experiments revealed that GLT-1 transporter expression in the nucleus accumbens of mice treated with repeated CA (1, 10 mg/kg) was enhanced relative to saline-treated mice. Repeated CA treatment (1 mg/kg) reduced the reinforcing efficacy of cocaine (0.56 mg/kg/inf) in mice maintained on a progressive-ratio (PR) schedule of reinforcement but did not affect acquisition of cocaine SA under fixed-ratio responding or acquisition or retention of learning. These findings suggest that the β-lactamase inhibitor CA can activate the cellular glutamate reuptake system in the brain reward circuit and reduce cocaine's reinforcing efficacy at 100-fold lower doses than CTX.
Collapse
Affiliation(s)
- Jae Kim
- Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA
| | - Joel John
- Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA
| | - Dianne Langford
- Department of Neurosciences, Temple University School of Medicine, Philadelphia, PA, USA
| | - Ellen Walker
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA
- Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA
| | - Sara Ward
- Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA
| | - Scott M Rawls
- Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA, USA.
- Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA.
| |
Collapse
|
5
|
Gasior M, Socała K, Nieoczym D, Wlaź P. Clavulanic acid does not affect convulsions in acute seizure tests in mice. J Neural Transm (Vienna) 2011; 119:1-6. [PMID: 21638029 PMCID: PMC3250610 DOI: 10.1007/s00702-011-0662-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Accepted: 05/18/2011] [Indexed: 11/26/2022]
Abstract
Clavulanic acid (CLAV) inhibits bacterial β-lactamases and is commonly used to aid antibiotic therapy. Prompted by the initial evidence suggestive of the potential anticonvulsant and neuroprotective properties of CLAV, the present study was undertaken to systematically evaluate its acute effects on seizure thresholds in seizure tests typically used in primary screening of potential antiepileptic drugs (AEDs). In the present study, 6-Hz seizure threshold, maximal electroshock seizure threshold (MEST) test, and intravenous pentylenetetrazole (i.v. PTZ) seizure tests were used to determine anticonvulsant effects of intraperitoneally (i.p.) administered CLAV in mice. Acute effects on motor coordination and muscle strength were assessed in the chimney and grip-strength tests, respectively. Doses of CLAV studied in the present study were either comparable or extended the doses reported in the literature to be effective against kainic acid-induced convulsions in mice or behaviorally active in rodents and monkeys. CLAV had no effect on seizure thresholds in the 6-Hz (64 ng/kg to 1 mg/kg) and MEST (64 ng/kg to 5 mg/kg) seizure tests. Similarly, CLAV had no effect on seizure thresholds for i.v. PTZ-induced myoclonic twitch, clonic convulsions, and tonic convulsions (64 ng/kg to 5 mg/kg). Finally, CLAV (64 ng/kg to 5 mg/kg) had no effect on the motor performance and muscle strength in the chimney and grip-strength tests, respectively. In summary, CLAV failed to affect seizure thresholds in three seizure tests in mice. Although the results of the present study do not support further development of CLAV as an AED, its beneficial effects in chronic epilepsy models warrant further evaluation owing to its, for example, potential neuroprotective properties.
Collapse
Affiliation(s)
- Maciej Gasior
- Clinical Research, Cephalon, Inc., 41 Moores Road, Frazer, PA 19355 USA
| | - Katarzyna Socała
- Department of Animal Physiology, Institute of Biology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland
| | - Dorota Nieoczym
- Department of Animal Physiology, Institute of Biology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland
| | - Piotr Wlaź
- Department of Animal Physiology, Institute of Biology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, Poland
| |
Collapse
|
6
|
R. Lewis J. Muscarine, imidazole, oxazole, thiazole and peptide alkaloids, and other miscellaneous alkaloids. Nat Prod Rep 1998. [DOI: 10.1039/a815371y] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
7
|
Cvetovich RJ, Senanayake CH, Amato JS, DiMichele LM, Bill TJ, Larsen RD, Shuman RF, Verhoeven TR, Grabowski EJJ. Practical Syntheses of 13-O-[(2-Methoxyethoxy)methyl]-22,23-dihydroavermectin B1 Aglycon [Dimedectin Isopropanol, MK-324] and 13-epi-O-(Methoxymethyl)-22,23-dihydroavermectin B1 Aglycon [L-694,554], Flea Active Ivermectin Analogues. J Org Chem 1997. [DOI: 10.1021/jo970187l] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Raymond J. Cvetovich
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Chris H. Senanayake
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Joseph S. Amato
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Lisa M. DiMichele
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Timothy J. Bill
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Robert D. Larsen
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - R. F. Shuman
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Thomas R. Verhoeven
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| | - Edward J. J. Grabowski
- Department of Process Research, Merck Research Laboratories, Division of Merck & Co., Inc., P.O. Box 2000, Rahway, New Jersey 07065
| |
Collapse
|